.png){kind=icon}
返回
Predicting future cognitive decline with hyperbolic stochastic coding
.png){kind=icon}
OA
AI
DOI：10.1016/j.media.2021.102009.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Hyperbolic geometry has been successfully applied in modeling brain cortical and subcortical surfaces with general topological structures. However, such approaches, similar to other surface-based brain morphology analysis methods, usually generate high dimensional features. It limits their statistical power in cognitive decline prediction research, especially in datasets with limited subject numbers. To address the above limitation, we propose a novel framework termed as hyperbolic stochastic coding (HSC). We first compute diffeomorphic maps between general topological surfaces by mapping them to a canonical hyperbolic parameter space with consistent boundary conditions and extracts critical shape features. Secondly, in the hyperbolic parameter space, we introduce a farthest point sampling with breadth-first search method to obtain ring-shaped patches. Thirdly, stochastic coordinate coding and max-pooling algorithms are adopted for feature dimension reduction. We further validate the proposed system by comparing its classification accuracy with some other methods on two brain imaging datasets for Alzheimer's disease (AD) progression studies. Our preliminary experimental results show that our algorithm achieves superior results on various classification tasks. Our work may enrich surface-based brain imaging research tools and potentially result in a diagnostic and prognostic indicator to be useful in individualized treatment strategies. (c) 2021 Elsevier B.V. All rights reserved.
Keyword:
Alzheimer's disease (AD)
Hyperbolic space
Ring-shaped patches
Sparse coding
Classification
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
11.8
论文数:
3.9K
被引数:
2.4W
机构
引用论文
分享收藏COMPARE: Classification of morphological patterns using adaptive regional elements比较: 使用自适应区域元素对形态模式进行分类
PREAI
分享收藏MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.png)
NEUROLOGYOAAI
NEUROLOGYIF8.5
OAAI分享收藏
查看更多内容